Innovation Pharmaceuticals Inc (IPIX)

[WhiteFordBronco]

https://www.google.com/amp/s/amp.cnn.com/cnn/2021/03/25/health/variants-eli-lilly-antibody-therapy-distribution-stops/index.html

Variants are making the monoclonal therapeutics ineffective.

https://bestlifeonline.com/antiviral-drugs-fauci-news/

Effective antivirals are highly sought after at the moment. I do wish brilacidin was in mild to moderate trial versus the moderate to severe. The focus in a mild to moderate trial might have highlighted the possible reduction in the viral load versus the moderate to severe trial focusing on recovery and mortality with viral load being a secondary endpoint.